UBS raised the firm’s price target on Cardinal Health (CAH) to $220 from $185 and keeps a Buy rating on the shares. The firm updated its model following the Q1 results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health price target raised to $232 from $208 at Baird
- Cardinal Health price target raised to $190 from $165 at Citi
- Cardinal Health Reports Strong Revenue Growth in Latest Quarter
- Cardinal Health price target raised to $216 from $180 at BofA
- Early notable gainers among liquid option names on October 30th